| Schedule of changes in Accumulated Other Comprehensive Income (Loss) |
Changes in Accumulated other comprehensive income (loss) attributable to Bio-Techne by component (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of June 30, 2022, net of tax |
|
$ |
8,069 |
|
$ |
(83,269) |
|
$ |
(75,200) |
Other comprehensive income (loss), before tax, attributable to Bio-Techne: : |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications (1) |
|
|
1,340 |
|
|
4,191 |
|
|
5,531 |
Amounts reclassified out |
|
|
4,526 |
|
|
152 |
|
|
4,678 |
Total other comprehensive income (loss), before tax, attributable to Bio-Techne: |
|
|
5,866 |
|
|
4,343 |
|
|
10,209 |
Tax expense |
|
|
(1,073) |
|
|
— |
|
|
(1,073) |
Total other comprehensive income (loss), net of tax, attributable to Bio-Techne: |
|
|
4,793 |
|
|
4,343 |
|
|
9,136 |
Balance as of June 30, 2023, net of tax(2) |
|
$ |
12,862 |
|
$ |
(78,926) |
|
$ |
(66,064) |
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(12,632) |
|
|
(9,941) |
|
|
(22,573) |
Amounts reclassified out |
|
|
10,317 |
|
|
3,210 |
|
|
13,527 |
Total other comprehensive income (loss), before tax |
|
|
(2,315) |
|
|
(6,731) |
|
|
(9,046) |
Tax expense |
|
|
(2,445) |
|
|
(761) |
|
|
(3,206) |
Total other comprehensive income (loss), net of tax |
|
|
(4,760) |
|
|
(7,492) |
|
|
(12,252) |
Balance as of June 30, 2024, net of tax(2) |
|
$ |
8,102 |
|
$ |
(86,418) |
|
$ |
(78,316) |
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(12,011) |
|
|
21,895 |
|
|
9,884 |
Amounts reclassified out |
|
|
8,448 |
|
|
2,761 |
|
|
11,209 |
Total other comprehensive income (loss), before tax |
|
|
(3,563) |
|
|
24,656 |
|
|
21,093 |
Tax expense |
|
|
(2,003) |
|
|
(654) |
|
|
(2,657) |
Total other comprehensive income (loss), net of tax |
|
|
(5,566) |
|
|
24,002 |
|
|
18,436 |
Balance as of June 30, 2025, net of tax(2) |
|
$ |
2,536 |
|
$ |
(62,416) |
|
$ |
(59,880) |
| (1) |
Amounts before reclassifications related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $33 thousand attributable to the non-controlling interest in Eminence as of June 30, 2023.
|
| (2) |
The Company had a net deferred tax liability for its cash flow hedge of $0.8 million, $2.5 million, and $4.0 million as of June 30, 2025, 2024 and 2023.
|
|